Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Artivion Inc AORT

Artivion, Inc. is a medical device company engaged in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures for patients with aortic disease, heart valve disease, aortic aneurysms, and dissections. The Company's segments include Medical Devices and Preservation Services. The Medical Devices segment... see more

Recent & Breaking News (NYSE:AORT)

Artivion Announces Presentation of New Clinical Data for On-X Aortic Heart Valve and AMDS at the 104th American Association for Thoracic Surgery (AATS) Annual Meeting

PR Newswire 4 days ago

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results

PR Newswire 10 days ago

Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference

PR Newswire April 1, 2024

Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

PR Newswire March 6, 2024

Artivion Reports Fourth Quarter and Full Year 2023 Financial Results

PR Newswire February 15, 2024

Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results

PR Newswire February 1, 2024

Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting

PR Newswire January 29, 2024

Artivion Obtains $350 Million in Senior Secured Credit Facilities

PR Newswire January 18, 2024

Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer

PR Newswire December 6, 2023

Artivion Announces Completion of Enrollment in PERSEVERE Trial

PR Newswire November 9, 2023

Artivion to Participate in Upcoming Investor Conferences

PR Newswire November 8, 2023

Artivion Reports Third Quarter 2023 Financial Results

PR Newswire November 2, 2023

Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results

PR Newswire October 19, 2023

Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin

PR Newswire October 5, 2023

Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting

PR Newswire October 5, 2023

Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference

PR Newswire September 26, 2023

Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase

PR Newswire September 14, 2023

Artivion Reports Second Quarter 2023 Financial Results

PR Newswire August 3, 2023

Artivion to Participate in Upcoming Investor Conferences

PR Newswire August 1, 2023

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2023 Financial Results

PR Newswire July 20, 2023